The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and TB 500: Injury Healing Peptides Jonathan L. Glashow posted on the topic LinkedIn FDA Peptide Reclassification 2026: What It Means for Providers Is BPC 157 Legal? Understanding Its Status and Implications The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few